论文部分内容阅读
目的观察血栓抽吸导管联用盐酸替罗非班和重组人脑利钠肽在急性心肌梗死直接冠脉介入治疗中的临床疗效。方法 30例急性心肌梗死患者,给予血栓抽吸、替罗非班、重组人脑利钠肽(rh-BNP)治疗。观察疗效及不良反应。结果 30例患者TIMI3级血流96.67%(29/30),主要不良心脏事件的发生率替罗非班组3.33%(1/30),出血并发症发生率16.67%(5/30)。结论在急性ST段抬高型心肌梗死(STEMI)的PCI介入治疗中,在血栓抽吸导管联合盐酸替罗非班治疗基础上再应用重组人脑利钠肽改善STEMI患者PCI术后梗死相关血管的TIMI血流效果好,PCI术后主要不良心脏事件发生率较低,出血并发症发生率低,值得推广。
Objective To observe the clinical effect of thrombus aspiration catheter combined with tirofiban hydrochloride and recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction by direct coronary intervention. Methods Thirty patients with acute myocardial infarction were treated with thrombolysis, tirofiban and recombinant human brain natriuretic peptide (rh-BNP). Observation of efficacy and adverse reactions. Results The TIMI grade 3 blood flow in 30 patients was 96.67% (29/30). The incidence of major adverse cardiac events was 3.33% (1/30) in tirofiban group and 16.67% (5/30) in bleeding complications. Conclusions In the PCI interventional treatment of STEMI patients, the combination of thrombus aspiration catheter and tirofiban hydrochloride is applied to improve the infarction-related blood vessels of STEMI patients after PCI TIMI blood flow is good, the incidence of major adverse cardiac events after PCI is lower, the incidence of bleeding complications is low, it is worth promoting.